These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37388683)

  • 41. Quantitative profiling of N-glycosylation of SARS-CoV-2 spike protein variants.
    Xie Y; Butler M
    Glycobiology; 2023 Apr; 33(3):188-202. PubMed ID: 36723867
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting Spike Glycans to Inhibit SARS-CoV2 Viral Entry.
    Guseman AJ; Rennick LJ; Nambulli S; Roy CN; Martinez DR; Yang DT; Bhinderwhala F; Vergara S; Baric RS; Ambrose Z; Duprex WP; Gronenborn AM
    bioRxiv; 2022 Dec; ():. PubMed ID: 36597530
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Core fucose-specific Pholiota squarrosa lectin (PhoSL) as a potent broad-spectrum inhibitor of SARS-CoV-2 infection.
    Yamasaki K; Adachi N; Ngwe Tun MM; Ikeda A; Moriya T; Kawasaki M; Yamasaki T; Kubota T; Nagashima I; Shimizu H; Tateno H; Morita K
    FEBS J; 2023 Jan; 290(2):412-427. PubMed ID: 36007953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody.
    Kumar S; Patel A; Lai L; Chakravarthy C; Valanparambil R; Reddy ES; Gottimukkala K; Davis-Gardner ME; Edara VV; Linderman S; Nayak K; Dixit K; Sharma P; Bajpai P; Singh V; Frank F; Cheedarla N; Verkerke HP; Neish AS; Roback JD; Mantus G; Goel PK; Rahi M; Davis CW; Wrammert J; Godbole S; Henry AR; Douek DC; Suthar MS; Ahmed R; Ortlund E; Sharma A; Murali-Krishna K; Chandele A
    Sci Adv; 2022 Oct; 8(40):eadd2032. PubMed ID: 36197988
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-resolution melting analysis to discriminate between the SARS-CoV-2 Omicron variants BA.1 and BA.2.
    Koshikawa T; Miyoshi H
    Biochem Biophys Rep; 2022 Sep; 31():101306. PubMed ID: 35791375
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2.
    Nikitin PA; DiMuzio JM; Dowling JP; Patel NB; Bingaman-Steele JL; Heimbach BC; Henriquez N; Nicolescu C; Polley A; Sikorski EL; Howanski RJ; Nath M; Shukla H; Scheaffer SM; Finn JP; Liang LF; Smith T; Storm N; McKay LGA; Johnson RI; Malsick LE; Honko AN; Griffiths A; Diamond MS; Sarma P; Geising DH; Morin MJ; Robinson MK
    Sci Immunol; 2022 Sep; 7(75):eabl9943. PubMed ID: 35771946
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
    Sheward DJ; Kim C; Ehling RA; Pankow A; Castro Dopico X; Dyrdak R; Martin DP; Reddy ST; Dillner J; Karlsson Hedestam GB; Albert J; Murrell B
    Lancet Infect Dis; 2022 Jun; 22(6):813-820. PubMed ID: 35305699
    [TBL] [Abstract][Full Text] [Related]  

  • 48. XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants.
    Vanhove B; Marot S; So RT; Gaborit B; Evanno G; Malet I; Lafrogne G; Mevel E; Ciron C; Royer PJ; Lheriteau E; Raffi F; Bruzzone R; Mok CKP; Duvaux O; Marcelin AG; Calvez V
    Front Immunol; 2021; 12():761250. PubMed ID: 34868003
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses.
    Wang CY; Peng WJ; Kuo BS; Ho YH; Wang MS; Yang YT; Chang PY; Shen YH; Hwang KP
    PLoS Pathog; 2023 Apr; 19(4):e1010870. PubMed ID: 37079651
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2.
    Zhang L; Narayanan KK; Cooper L; Chan KK; Devlin CA; Aguhob A; Shirley K; Rong L; Rehman J; Malik AB; Procko E
    bioRxiv; 2022 Mar; ():. PubMed ID: 35378764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SARS-CoV-2 neutralizing camelid heavy-chain-only antibodies as powerful tools for diagnostic and therapeutic applications.
    Schlör A; Hirschberg S; Amor GB; Meister TL; Arora P; Pöhlmann S; Hoffmann M; Pfaender S; Eddin OK; Kamhieh-Milz J; Hanack K
    Front Immunol; 2022; 13():930975. PubMed ID: 36189209
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus.
    Shih YP; Chen CY; Liu SJ; Chen KH; Lee YM; Chao YC; Chen YM
    J Virol; 2006 Nov; 80(21):10315-24. PubMed ID: 17041212
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.
    D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P
    Front Immunol; 2022; 13():981693. PubMed ID: 36225911
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Omicron BA.1 Mutations in SARS-CoV-2 Spike Lead to Reduced T-Cell Response in Vaccinated and Convalescent Individuals.
    Emmelot ME; Vos M; Boer MC; Rots NY; de Wit J; van Els CACM; Kaaijk P
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891550
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode.
    Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H
    J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of SARS-CoV-2 wild-type (Wuhan-Hu-1) and Delta (B.1.617.2) strains by marine sulfated glycans.
    Dwivedi R; Sharma P; Farrag M; Kim SB; Fassero LA; Tandon R; Pomin VH
    Glycobiology; 2022 Sep; 32(10):849-854. PubMed ID: 35788318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk evaluation and mitigation strategies for newly detected SARS-CoV-2 Omicron BF.7 subvariant: A brief report.
    Nazmunnahar ; Ahmed I; Islam MR
    Health Sci Rep; 2023 Mar; 6(3):e1127. PubMed ID: 36875932
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.
    Strasser ZH; Greifer N; Hadavand A; Murphy SN; Estiri H
    JAMA Netw Open; 2022 Oct; 5(10):e2238354. PubMed ID: 36282501
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nano-size dependent protein corona formation by SARS-CoV-2 Omicron spike protein over gold nano-colloid and reversible aggregation.
    Yokoyama K; Lam T; Santariello J; Ichiki A
    Colloids Surf A Physicochem Eng Asp; 2022 Aug; 647():128967. PubMed ID: 35466287
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022.
    Cheng SM; Mok CKP; Chan KC; Ng SS; Lam BH; Luk LL; Ko FW; Chen C; Yiu K; Li JK; Chan KK; Tsang LC; Poon LL; Hui DS; Peiris M
    Euro Surveill; 2022 May; 27(18):. PubMed ID: 35514306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.